Funder
Natural Science Foundation of Jiangxi Province
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Thaler J, Lisman T, Quehenberger P, et al. Intraperitoneal activation of coagulation and fibrinolysis in patients with cirrhosis and ascites. Thromb Haemost. 2022;122(3):353–62. https://doi.org/10.1055/a-1515-9529.
2. Li CJ, Yang ZH, Lu FG, et al. Clinical significance of fibrotic, haemostatic and endotoxic changes in patients with liver cirrhosis. Acta Gastroenterol Belg. 2018;81(3):404–9.
3. Peng J, He G, Chen H, et al. Study on correlation between coagulation indexes and disease progression in patients with cirrhosis. Am J Transl Res. 2021;13(5):4614–23.
4. Fuentes A, Gordon-Burroughs S, Hall JB, et al. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis. Ther Drug Monit. 2015;37(1):40–4. https://doi.org/10.1097/FTD.0000000000000105.
5. Ku YH, Yu WL. Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria? Infect Genet Evol. 2021;88: 104707. https://doi.org/10.1016/j.meegid.2021.104707.